|
|
Post by cjm18 on Jun 27, 2019 10:12:11 GMT -5
|
|
|
|
Post by akemp3000 on Jun 27, 2019 10:17:27 GMT -5
It's not going to take long for time-in-range to replace the antiquated A1c as this next technology generation moves forward. It will take longer for the FDA, ADA and health care system in general to change their standards and protocols but this is really good news.
|
|
|
|
Post by cjm18 on Jun 27, 2019 10:41:31 GMT -5
Time in range as soc would help cgms. Cgms help Afrezza.
Dexcom must be wetting themselves over apples potential cgm.
Mannkind just needs to move the pipeline forward slowly but surely to get there.
|
|
|
|
Post by agedhippie on Jun 27, 2019 12:24:57 GMT -5
It's not going to take long for time-in-range to replace the antiquated A1c as this next technology generation moves forward. It will take longer for the FDA, ADA and health care system in general to change their standards and protocols but this is really good news. One Drop is not going to help with TIR as it is finger stick testing, not a CGM. |
|
|
|
Post by agedhippie on Jun 27, 2019 12:27:39 GMT -5
Time in range as soc would help cgms. Cgms help Afrezza. Dexcom must be wetting themselves over apples potential cgm. Mannkind just needs to move the pipeline forward slowly but surely to get there. I think you will find Dexcom is focused on selling their product rather than worrying if one day Apple will create a CGM. For the record I don't see Apple doing that, as it is far easier to interface with everyone else's CGMs. |
|
